PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=6750238
Dickman P.S., Liotta L.A., Triche T.J.
Ewing's sarcoma. Characterization in established cultures and evidence of its histogenesis.
Lab. Invest. 47:375-382(1982)

PubMed=3004699; DOI=10.1016/0165-4608(86)90001-4
Whang-Peng J., Triche T.J., Knutsen T., Miser J.S., Kao-Shan C.-S., Tsai S., Israel M.A.
Cytogenetic characterization of selected small round cell tumors of childhood.
Cancer Genet. Cytogenet. 21:185-208(1986)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3390826
McKeon C., Thiele C.J., Ross R.A., Kwan M., Triche T.J., Miser J.S., Israel M.A.
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Cancer Res. 48:4307-4311(1988)

PubMed=2620246; DOI=10.3109/07357908909041371
Gulati S.C., Kwon J.-H., Atzpodien J., Triche T.J., Colvin O.M., Clarkson B.D. Sr.
In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantation.
Cancer Invest. 7:411-416(1989)

PubMed=29464090; DOI=10.18632/oncotarget.23815; PMCID=PMC5814230
Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W., Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M., Meltzer J., Farwick N., Greune L., Rossig C.
T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.
Oncotarget 9:6536-6549(2018)

PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014; PMCID=PMC6520468
Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C., Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J., Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N., Muller I., Walles H., Hartmann W., Rossig C.
EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.
Mol. Ther. 27:933-946(2019)